Navigation Links
Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics
Date:1/8/2014

TOKYO, SEATTLE, and LEBANON, N.H., Jan. 8, 2014 /PRNewswire/ -- Daiichi Sankyo, Co., Ltd., Virtici, LLC and Celdara Medical, LLC announced today that they have entered into a collaboration to jointly investigate novel therapeutic candidates and thereby further strengthen the Daiichi Sankyo developmental pipeline across multiple therapeutic areas.

Virtici and Celdara Medical are affiliated, independent companies that build and develop pipelines of high potential therapeutic assets.  The collaboration is intended to accelerate the time from discovery to development with the potential to deliver first-in-class treatments that address significant unmet medical needs.  Funding is channeled into the most promising targets to drive early research before moving into larger scale clinical development. 

"This collaboration strengthens our ability to access potential breakthrough innovation, and demonstrates our continued commitment to working with partners at the forefront of science," said Mahmoud Ghazzi, M.D., Ph.D., Global Head of Development, Daiichi Sankyo, Co. Ltd.  "By augmenting in-house research and other development avenues, these focused, exclusive, indication-targeted partnerships can accelerate medical innovations into the clinic and ultimately to patients."

"We are extremely pleased to be working with Daiichi Sankyo," said Neil Fanger, Ph.D., President and Chief Executive Officer of Virtici. "Using our unique model, infrastructure and capabilities, we can help further advance Daiichi Sankyo's strong track record of innovative drug development. This collaboration leverages the complementary capabilities and synergies between our firms."

"This alliance represents a new partnership paradigm for Virtici and Celdara Medical while validating our underlying development model. Daiic
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
2. Daiichi Sankyos Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
3. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
4. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
5. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
6. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
7. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
8. Kalila Medical Announces CE Mark Approval For The Vado Steerable Sheath Used During Atrial Fibrillation Procedures
9. Puritan Medical Products erhält zwei neue Patente für beflockte Tupfer in Japan
10. Agile Therapeutics Appoints Dr. Elizabeth Ijeoma Onyemelukwe Garner as Chief Medical Officer
11. Ensil Canada is Launching a New Medical Device: Publicly Traded Companies Are Invited to Acquire This Technology or Partner with Ensil Canada on the Marketing and Distribution of This New Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 Across the global healthcare landscape, ... in clinical development, market education, and regulatory compliance. As ... Affairs function is expected to increase in prominence and ... According to research by benchmarking firm, Best Practices, ... dedicated to Medical Affairs. Among companies in ...
(Date:3/27/2015)... March 27, 2015 Object recognition technology has ... impaired and elderly. The VelaSense ® ... lead more independent, productive and fulfilling lives. VelaSense ® ... allow users to identify objects from a one million ... create customized object databases for personal use. ...
(Date:3/27/2015)... Ga. , March 27, 2015  Holographic Optical ... in the field of holographic medical imaging, is entering ... its Kickstarter campaign. Launching on April 20 th , ... and Voxbox Pro. The 8-inch and 22-inch displays will ... home for the first time. In addition to the ...
Breaking Medicine Technology:Medical Affairs Capabilities Expanding in Emerging Marketplaces 2VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3
... MYL ) today announced that its subsidiary Mylan ... and Drug Administration (FDA) for its Abbreviated New Drug Application ... mg, 10 mg, 15 mg, and 20 mg. This product ... ® , which is indicated for the treatment of schizophrenia ...
... Young Innovations, Inc. (NASDAQ: YDNT ) today announced sales ... Sales for the first quarter of 2012 were ... the first quarter of 2011. Income from operations increased 5.3% to ... in the first quarter of 2011. Net income increased 5.6% to ...
Cached Medicine Technology:Mylan Launches Generic Version of Zyprexa® Tablets 2Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 2Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 3Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 4
(Date:3/28/2015)... NY (PRWEB) March 28, 2015 An ... a problem which could prove critical to organizations that ... testing, a critical aspect of data security, is worsening ... industry data security report, every major category out of ... and penetration testing. “With all the craziness that has ...
(Date:3/28/2015)... March 28, 2015 Delaying rotator cuff ... necessary, according to research presented today at the American ... Day. , “Our study compared results for 170 patients ... an additional glenohumeral joint capsule release procedure to relieve ... MD, PhD, lead author from St. George Hospital in ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Annual Conference to be held April 10-11, 2015 ... OH. , The OPTA Annual Conference offers ... and services. , Representatives from Aureus Medical’s ...
(Date:3/28/2015)... Purity Products®, a leading direct to ... of their revolutionary new weight loss product, MuffinStop™. ... placebo-controlled clinical studies to be effective in reducing ... is a combination of two traditionally used botanical ... to create one of the most innovative weight ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 In her mid-forties ... prevented her from working, Monica K. arrived at JET ... mending department quiet, defensive and scared. The owners and staff ... Support Services (EPSS) to offer jobs to challenged residents ... patience and a willingness to begin with the end in ...
Breaking Medicine News(10 mins):Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3
... Researchers from the University of Pennsylvania School of Medicine ... determines the development of many cell types, and is ... for the maintenance of stem cells. The findings appear ... inhibitors of Notch may not affect bone marrow stem ...
... 1995, Tapped to Steer the World,s Largest Organization ... WHITE PLAINS, N.Y., April 10 The Leukemia & ... chief executive,officer, with the task of leading the world,s ... strives to find cures and,prolong and enhance the lives ...
... survived exposure, study reports, , , THURSDAY, April 10 (HealthDay ... anthrax vaccine that provides protection against the potentially deadly ... and combining two of anthrax,s lethal toxins, the researchers ... be more effective than vaccines that contain just one ...
... - 7,000 deaths ... significantly reduces pharmacy error risk, - Half of consumers choose their ... ... April 10 One-third of America,s 225,million prescription-takers now report experiencing ...
... N.J., April 10 Hooper Holmes,(Amex: HH ) today ... Executive Officer and that Benjamin A. Currier will continue as,Chairman ... a member of the,Board since May 30, 2007, had been ... basis on February 6, 2008., John W. Remshard, who ...
... state,s elderly, disabled, and ... ... cut hundreds of millions of dollars from Medicaid,programs for the elderly, disabled ... the leaders of Florida,s safety net,hospitals warned today., Besides jeopardizing the ...
Cached Medicine News:Health News:Developing cancer treatments directed at critical developmental pathway 2Health News:The Leukemia & Lymphoma Society Announces Appointment of New President and CEO 2Health News:Researchers Pursuing Nasal Anthrax Vaccine 2Health News:Researchers Pursuing Nasal Anthrax Vaccine 3Health News:Prescription For Disaster: One-Third of Consumers Experience Prescription Errors, New Survey Finds 2Health News:Prescription For Disaster: One-Third of Consumers Experience Prescription Errors, New Survey Finds 3Health News:Hooper Holmes Names Roy Bubbs President and CEO, Benjamin Currier Continues as Chairman 2Health News:Hooper Holmes Names Roy Bubbs President and CEO, Benjamin Currier Continues as Chairman 3Health News:Massive Medicaid Cuts Will Impact All Floridians, Safety Net Hospital Leaders Warn 2Health News:Massive Medicaid Cuts Will Impact All Floridians, Safety Net Hospital Leaders Warn 3
RIA kit for the quantitative determination of autoantibodies to IA-2 in serum...
ELISA kit for the quantitative determination of autoantibodies to IA-2 in serum...
Inquire...
Inquire...
Medicine Products: